Laboratory of Molecular Biology
Head, Solid Tumor Immunotherapy Section
Principal Investigator

National Cancer Institute
10 Center Drive
Building 37, Room 5116
Bethesda, MD 20892

Phone: 301-451-8742
Fax: 301-402-9469
hassanr@mail.nih.gov

Dr. Hassan is a medical oncologist and senior investigator at the National Cancer Institute (NCI). Dr. Hassan has focused on developing novel therapies for the treatment of malignant mesothelioma. He is currently conducting clinical trials of two different immunotherapy agents targeting the tumor antigen mesothelin that was discovered at NCI. Dr. Hassan is the chairman of the Science Advisory Board of the Meso Foundation. He is a recipient of the American Society of Clinical Oncology Career Development Award as well as the National Institutes of Health K23 Career Development Award.

Dr. Hassan's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with mesothelioma. Click on the trial(s) below for additional details, including a summary of eligibility criteria, study outline, and information on how to contact Dr. Hassan and his staff directly.

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma NCI-09-C-0077

A Phase I, Single Center, Dose-Escalation Study of SS1(dsFv)-PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma NCI-08-C-0026